{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:55:38Z","timestamp":1764791738595,"version":"3.46.0"},"reference-count":30,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Serologic tests on automated immunology analyzers are increasingly used to monitor acquired immunity against SARS-CoV-2. The heterogeneity of assays raises concerns about their diagnostic performance and comparability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To test sera from formerly infected individuals for SARS-CoV-2 antibodies by using 6 automated serology assays and a pseudoneutralization test (PNT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Six SARS-CoV-2 serology assays were used to assess 954 samples collected during a 12-month period from 315 COVID-19 convalescents. The tests determined either antibodies against the viral nucleocapsid (anti-NC) or spike protein (anti-S). Two assays did not distinguish between antibody classes, whereas the others selectively measured immunoglobulin G (IgG) antibodies. PNT was used to detect the presence of neutralizing antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Comparison of qualitative results showed only slight to moderate concordance between the assays (Cohen \u03ba &amp;lt; 0.57). Significant correlations (P &amp;lt; .001) were observed between the antibody titers from all quantitative assays. However, titer changes were not detected equally. A total anti-S assay measured an increase in 128 of 172 cases (74%) of a suitable subset, whereas all IgG anti-S tests reported decreases in at least 118 (69%). Regarding the PNT results, diagnostic sensitivities of 89% or greater were achieved with positive predictive values of at least 93%. In contrast, specificity changed substantially over time, varying from 20% to 100%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Comparability of serologic SARS-CoV-2 antibody tests is rather poor. Owing to different diagnostic specificities, the tested assays were not equally capable of capturing changes in antibody titers. However, with thoroughly validated cutoffs, IgG-selective anti-S assays are a reliable surrogate test for SARS-CoV-2 neutralizing antibodies in former COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2021-0604-sa","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T16:38:17Z","timestamp":1643301497000},"page":"538-546","source":"Crossref","is-referenced-by-count":4,"title":["Longitudinal Comparison of Automated SARS-CoV-2 Serology Assays in Assessing Virus Neutralization Capacity in COVID-19 Convalescent Sera"],"prefix":"10.5858","volume":"146","author":[{"given":"Tobias","family":"Niedrist","sequence":"first","affiliation":[{"name":"From the Clinical Institute of Medical and Chemical Laboratory Diagnostics (Niedrist, Herrmann), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Drexler","sequence":"additional","affiliation":[{"name":"Department of Blood Group Serology and Transfusion Medicine (Drexler, Torreiter, Schlenke), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Paul","family":"Torreiter","sequence":"additional","affiliation":[{"name":"Department of Blood Group Serology and Transfusion Medicine (Drexler, Torreiter, Schlenke), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Matejka","sequence":"additional","affiliation":[{"name":"Biobank Graz (Matejka, Strahlhofer-Augsten, Kral, Riegler, G\u00fclly), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Strahlhofer-Augsten","sequence":"additional","affiliation":[{"name":"Biobank Graz (Matejka, Strahlhofer-Augsten, Kral, Riegler, G\u00fclly), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Kral","sequence":"additional","affiliation":[{"name":"Biobank Graz (Matejka, Strahlhofer-Augsten, Kral, Riegler, G\u00fclly), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Skaiste","family":"Riegler","sequence":"additional","affiliation":[{"name":"Biobank Graz (Matejka, Strahlhofer-Augsten, Kral, Riegler, G\u00fclly), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"G\u00fclly","sequence":"additional","affiliation":[{"name":"Biobank Graz (Matejka, Strahlhofer-Augsten, Kral, Riegler, G\u00fclly), Medical University of Graz, Graz, Austria"},{"name":"Center for Medical Research (G\u00fclly), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Zurl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases in the Department of Internal Medicine (Zurl, Kriegl, Krause), Medical University of Graz, Graz, Austria"},{"name":"Division of General Paediatrics in the Department of Paediatrics and Adolescents Medicine (Zurl), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Kriegl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases in the Department of Internal Medicine (Zurl, Kriegl, Krause), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Krause","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases in the Department of Internal Medicine (Zurl, Kriegl, Krause), Medical University of Graz, Graz, Austria"},{"name":"BioTechMed Graz, Graz, Austria (Krause)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Berghold","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Statistics and Documentation (Berghold), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Steinmetz","sequence":"additional","affiliation":[{"name":"Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine (Steinmetz), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schlenke","sequence":"additional","affiliation":[{"name":"Department of Blood Group Serology and Transfusion Medicine (Drexler, Torreiter, Schlenke), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Herrmann","sequence":"additional","affiliation":[{"name":"From the Clinical Institute of Medical and Chemical Laboratory Diagnostics (Niedrist, Herrmann), Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"2024011206340018800_i1543-2165-146-5-538-b01","doi-asserted-by":"crossref","unstructured":"Benton\n              DJ,\n            \n            \n              Wrobel\n              AG,\n            \n            \n              Xu\n              P,\n            \n            et al.\n          \n          Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion.\n\t\t\t\t\tNature.\n\t\t\t\t\t2020;\n\t\t\t\t\t588(7837):\n\t\t\t\t\t327\u2013\n\t\t\t\t\t330.\n\t\t\t\t\tdoi:10.1038\/s41586-020-2772-0","DOI":"10.1038\/s41586-020-2772-0"},{"key":"2024011206340018800_i1543-2165-146-5-538-b02","doi-asserted-by":"crossref","unstructured":"Bai\n              Z,\n            \n            \n              Cao\n              Y,\n            \n            \n              Liu\n              W,\n            \n            \n              Li\n              J.\n            \n          \n          The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation.\n\t\t\t\t\tViruses.\n\t\t\t\t\t2021;\n\t\t\t\t\t13(6):\n\t\t\t\t\t1115.\n\t\t\t\t\tdoi:10.3390\/v13061115","DOI":"10.3390\/v13061115"},{"key":"2024011206340018800_i1543-2165-146-5-538-b03","doi-asserted-by":"crossref","unstructured":"Cao\n              Y,\n            \n            \n              Su\n              B,\n            \n            \n              Guo\n              X,\n            \n            et al.\n          \n          Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.\n\t\t\t\t\tCell.\n\t\t\t\t\t2020;\n\t\t\t\t\t182(1):\n\t\t\t\t\t73\u2013\n\t\t\t\t\t84.\n\t\t\t\t\tdoi:10.1016\/j.cell.2020.05.025","DOI":"10.1016\/j.cell.2020.05.025"},{"key":"2024011206340018800_i1543-2165-146-5-538-b04","doi-asserted-by":"crossref","unstructured":"Kohmer\n              N,\n            \n            \n              R\u00fchl\n              C,\n            \n            \n              Ciesek\n              S,\n            \n            \n              Rabenau\n              HF.\n            \n          \n          Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies.\n\t\t\t\t\tJ Clin Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t10(10):\n\t\t\t\t\t2128.\n\t\t\t\t\tdoi:10.3390\/jcm10102128","DOI":"10.3390\/jcm10102128"},{"key":"2024011206340018800_i1543-2165-146-5-538-b05","doi-asserted-by":"crossref","unstructured":"Kral\n              S,\n            \n            \n              Banfi\n              C,\n            \n            \n              Niedrist\n              T,\n            \n            et al.\n          \n          Long-lasting immune response to a mild course of PCR-confirmed SARS-CoV-2 infection: a cohort study.\n\t\t\t\t\tJ Infect.\n\t\t\t\t\t2021;\n\t\t\t\t\t83(5):\n\t\t\t\t\t607\u2013\n\t\t\t\t\t635.\n\t\t\t\t\tdoi:10.1016\/j.jinf.2021.08.030","DOI":"10.1016\/j.jinf.2021.08.030"},{"key":"2024011206340018800_i1543-2165-146-5-538-b06","unstructured":"Elecsys Anti-SARS-CoV-2 S [package insert].\n          Mannheim, Germany:\n\t\t\t\t\tRoche Diagnostics GmbH;2021."},{"key":"2024011206340018800_i1543-2165-146-5-538-b07","unstructured":"SARS-CoV-2 IgG II Quant [package insert].\n          Sligo, Ireland:\n\t\t\t\t\tAbbott Ireland;2020."},{"key":"2024011206340018800_i1543-2165-146-5-538-b08","unstructured":"LIAISON SARS-CoV-2 S1\/S2 IgG [package insert].\n          Saluggia, Italy:\n\t\t\t\t\tDiaSorin SpA;2020."},{"key":"2024011206340018800_i1543-2165-146-5-538-b09","unstructured":"LIAISON SARS-CoV-2 TrimericS IgG [package insert].\n          Saluggia, Italy:\n\t\t\t\t\tDiaSorin SpA;2020."},{"key":"2024011206340018800_i1543-2165-146-5-538-b10","unstructured":"Elecsys Anti-SARS-CoV-2 [package insert].\n          Mannheim, Germany:\n\t\t\t\t\tRoche Diagnostics GmbH;2020."},{"key":"2024011206340018800_i1543-2165-146-5-538-b11","unstructured":"SARS-CoV-2 IgG [package insert].\n          Sligo, Ireland:\n\t\t\t\t\tAbbott Ireland;2020."},{"key":"2024011206340018800_i1543-2165-146-5-538-b12","doi-asserted-by":"crossref","unstructured":"Schallier\n              A,\n            \n            \n              De Baets\n              S,\n            \n            \n              De Bruyne\n              D,\n            \n            \n              Dauwe\n              K,\n            \n            \n              Herpol\n              M,\n            \n            \n              Couck\n              P.\n            \n          \n          Assay dependence of long-term kinetics of SARS-CoV-2 antibodies.\n\t\t\t\t\tDiagn Microbiol Infect Dis.\n\t\t\t\t\t2021;\n\t\t\t\t\t100(4):\n\t\t\t\t\t115403.\n\t\t\t\t\tdoi:10.1016\/j.diagmicrobio.2021.115403","DOI":"10.1016\/j.diagmicrobio.2021.115403"},{"key":"2024011206340018800_i1543-2165-146-5-538-b13","doi-asserted-by":"crossref","unstructured":"Dorigatti\n              I,\n            \n            \n              Lavezzo\n              E,\n            \n            \n              Manuto\n              L,\n            \n            et al.\n          \n          SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2021;\n\t\t\t\t\t12(1):\n\t\t\t\t\t4383.\n\t\t\t\t\tdoi:10.1038\/s41467-021-24622-7","DOI":"10.1038\/s41467-021-25321-z"},{"key":"2024011206340018800_i1543-2165-146-5-538-b14","doi-asserted-by":"crossref","unstructured":"Sterlin\n              D,\n            \n            \n              Mathian\n              A,\n            \n            \n              Miyara\n              M,\n            \n            et al.\n          \n          IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med.\n          2021;\n\t\t\t\t\t13(577):eabd2223.doi:10.1126\/scitranslmed.abd2223","DOI":"10.1126\/scitranslmed.abd2223"},{"key":"2024011206340018800_i1543-2165-146-5-538-b15","doi-asserted-by":"crossref","unstructured":"Underwood\n              AP,\n            \n            \n              S\u00f8lund\n              C,\n            \n            \n              Fernandez-Antunez\n              C,\n            \n            et al.\n          \n          Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.\n\t\t\t\t\tEBioMedicine.\n\t\t\t\t\t2021;\n\t\t\t\t\t71:\n\t\t\t\t\t103519.\n\t\t\t\t\tdoi:10.1016\/j.ebiom.2021.103519","DOI":"10.1016\/j.ebiom.2021.103519"},{"key":"2024011206340018800_i1543-2165-146-5-538-b16","doi-asserted-by":"crossref","unstructured":"Ivanov\n              A,\n            \n            \n              Semenova\n              E.\n            \n          \n          Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection.\n\t\t\t\t\tJ Med Virol.\n\t\t\t\t\t2021;\n\t\t\t\t\t93(10):\n\t\t\t\t\t5953\u2013\n\t\t\t\t\t5960.\n\t\t\t\t\tdoi:10.1002\/jmv.27166","DOI":"10.1002\/jmv.27166"},{"key":"2024011206340018800_i1543-2165-146-5-538-b17","doi-asserted-by":"crossref","unstructured":"Jung\n              K,\n            \n            \n              Shin\n              S,\n            \n            \n              Nam\n              M,\n            \n            et al.\n          \n          Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.\n\t\t\t\t\tJ Clin Lab Anal.\n\t\t\t\t\t2021;\n\t\t\t\t\t35(9):\n\t\t\t\t\te23921.\n\t\t\t\t\tdoi:10.1002\/jcla.23921","DOI":"10.1002\/jcla.23921"},{"key":"2024011206340018800_i1543-2165-146-5-538-b18","doi-asserted-by":"crossref","unstructured":"Perkmann\n              T,\n            \n            \n              Perkmann-Nagele\n              N,\n            \n            \n              Koller\n              T,\n            \n            et al.\n          \n          Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays.\n\t\t\t\t\tMicrobiol Spectr.\n\t\t\t\t\t2021;\n\t\t\t\t\t9(1):\n\t\t\t\t\te0024721.\n\t\t\t\t\tdoi:10.1128\/Spectrum.00247-21","DOI":"10.1128\/Spectrum.00247-21"},{"key":"2024011206340018800_i1543-2165-146-5-538-b19","unstructured":"First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) [package insert].\n          Hertfordshire, United Kingdom: WHO Laboratory for Biological Standards, National Institute for Biological Standards and Control;\n          2020"},{"key":"2024011206340018800_i1543-2165-146-5-538-b20","doi-asserted-by":"crossref","unstructured":"Ferrari\n              D,\n            \n            \n              Clementi\n              N,\n            \n            \n              Span\u00f2\n              SM,\n            \n            et al.\n          \n          Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects.\n\t\t\t\t\tClin Chim Acta.\n\t\t\t\t\t2021;\n\t\t\t\t\t522:\n\t\t\t\t\t144\u2013\n\t\t\t\t\t151.\n\t\t\t\t\tdoi:10.1016\/j.cca.2021.08.024","DOI":"10.1016\/j.cca.2021.08.024"},{"key":"2024011206340018800_i1543-2165-146-5-538-b21","doi-asserted-by":"crossref","unstructured":"Aydillo\n              T,\n            \n            \n              Rombauts\n              A,\n            \n            \n              Stadlbauer\n              D,\n            \n            et al.\n          \n          Immunological imprinting of the antibody response in COVID-19 patients.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2021;\n\t\t\t\t\t12(1):\n\t\t\t\t\t3781.\n\t\t\t\t\tdoi:10.1038\/s41467-021-23977-1.","DOI":"10.1038\/s41467-021-23977-1"},{"key":"2024011206340018800_i1543-2165-146-5-538-b22","doi-asserted-by":"crossref","unstructured":"Resman Rus\n              K,\n            \n            \n              Korva\n              M,\n            \n            \n              Knap\n              N,\n            \n            \n              Av\u0161i\ufffd? \u017dupanc\n              T,\n            \n            \n              Poljak\n              M.\n            \n          \n          Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.\n\t\t\t\t\tJ Clin Virol.\n\t\t\t\t\t2021;\n\t\t\t\t\t139:\n\t\t\t\t\t104820.\n\t\t\t\t\tdoi:10.1016\/j.jcv.2021.104820","DOI":"10.1016\/j.jcv.2021.104820"},{"key":"2024011206340018800_i1543-2165-146-5-538-b23","doi-asserted-by":"crossref","unstructured":"Rubio-Acero\n              R,\n            \n            \n              Castelletti\n              N,\n            \n            \n              Fingerle\n              V,\n            \n            et al.\n          \n          In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-\/symptomatic patients.\n\t\t\t\t\tInfect Dis Ther.\n\t\t\t\t\t2021;\n\t\t\t\t\t10(3):\n\t\t\t\t\t1505\u2013\n\t\t\t\t\t1518.\n\t\t\t\t\tdoi:10.1007\/s40121-021-00475-x","DOI":"10.1007\/s40121-021-00475-x"},{"key":"2024011206340018800_i1543-2165-146-5-538-b24","doi-asserted-by":"crossref","unstructured":"Grenache\n              DG,\n            \n            \n              Ye\n              C,\n            \n            \n              Bradfute\n              SB.\n            \n          \n          Correlation of SARS-CoV-2 neutralizing antibodies to an automated chemiluminescent serological immunoassay.\n\t\t\t\t\tJ Appl Lab Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t6(2):\n\t\t\t\t\t491\u2013\n\t\t\t\t\t495.\n\t\t\t\t\tdoi:10.1093\/jalm\/jfaa195","DOI":"10.1093\/jalm\/jfaa195"},{"key":"2024011206340018800_i1543-2165-146-5-538-b25","doi-asserted-by":"crossref","unstructured":"Kober\n              C,\n            \n            \n              Manni\n              S,\n            \n            \n              Wolff\n              S,\n            \n            et al.\n          \n          IgG3 and IgM identified as key to SARS-CoV-2 neutralization in convalescent plasma pools.\n\t\t\t\t\tPLoS One.\n\t\t\t\t\t2022;\n\t\t\t\t\t17(1):\n\t\t\t\t\te0262162.\n\t\t\t\t\tdoi:10.1371\/journal.pone.0262162","DOI":"10.1371\/journal.pone.0262162"},{"key":"2024011206340018800_i1543-2165-146-5-538-b26","doi-asserted-by":"crossref","unstructured":"Patil\n              HP,\n            \n            \n              Rane\n              PS,\n            \n            \n              Shrivastava\n              S,\n            \n            et al.\n          \n          Antibody (IgA, IgG, and IgG subtype) responses to SARS-CoV-2 in severe and nonsevere COVID-19 patients.\n\t\t\t\t\tViral Immunol.\n\t\t\t\t\t2021;\n\t\t\t\t\t34(3):\n\t\t\t\t\t201\u2013\n\t\t\t\t\t209.\n\t\t\t\t\tdoi:10.1089\/vim.2020.0321","DOI":"10.1089\/vim.2020.0321"},{"key":"2024011206340018800_i1543-2165-146-5-538-b27","doi-asserted-by":"crossref","unstructured":"Meyer\n              B,\n            \n            \n              Reimerink\n              J,\n            \n            \n              Torriani\n              G,\n            \n            et al.\n          \n          Validation and clinical evaluation of a SARS-CoV-2\u200asurrogate virus neutralisation test (sVNT).\n\t\t\t\t\tEmerg Microbes Infect.\n\t\t\t\t\t2020;\n\t\t\t\t\t9(1):\n\t\t\t\t\t2394\u2013\n\t\t\t\t\t2403.\n\t\t\t\t\tdoi:10.1080\/22221751.2020.1835448","DOI":"10.1080\/22221751.2020.1835448"},{"key":"2024011206340018800_i1543-2165-146-5-538-b28","doi-asserted-by":"crossref","unstructured":"von Rhein\n              C,\n            \n            \n              Scholz\n              T,\n            \n            \n              Henss\n              L,\n            \n            et al.\n          \n          Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.\n\t\t\t\t\tJ Virol Methods.\n\t\t\t\t\t2021;\n\t\t\t\t\t288:\n\t\t\t\t\t114031.\n\t\t\t\t\tdoi:10.1016\/j.jviromet.2020.114031","DOI":"10.1016\/j.jviromet.2020.114031"},{"key":"2024011206340018800_i1543-2165-146-5-538-b29","doi-asserted-by":"crossref","unstructured":"Barnes\n              TW,\n            \n            \n              Schulte-Pelkum\n              J,\n            \n            \n              Steller\n              L,\n            \n            et al.\n          \n          Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.\n\t\t\t\t\tClin Immunol.\n\t\t\t\t\t2021;\n\t\t\t\t\t232:\n\t\t\t\t\t108871.\n\t\t\t\t\tdoi:10.1016\/j.clim.2021.108871","DOI":"10.1016\/j.clim.2021.108871"},{"key":"2024011206340018800_i1543-2165-146-5-538-b30","doi-asserted-by":"crossref","unstructured":"Di Germanio\n              C,\n            \n            \n              Simmons\n              G,\n            \n            \n              Kelly\n              K,\n            \n            et al.\n          \n          SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: dependency on assay format and applicability to serosurveillance.\n\t\t\t\t\tTransfusion.\n\t\t\t\t\t2021;\n\t\t\t\t\t61(9):\n\t\t\t\t\t2677\u2013\n\t\t\t\t\t2687.\n\t\t\t\t\tdoi:10.1111\/trf.16555","DOI":"10.1111\/trf.16555"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/5\/538\/3314853\/i1543-2165-146-5-538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/5\/538\/3314853\/i1543-2165-146-5-538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:38Z","timestamp":1764790898000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/146\/5\/article-p538.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,1,27]]},"published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2021-0604-sa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"type":"electronic","value":"1543-2165"},{"type":"print","value":"0003-9985"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}